^
BIOMARKER:

PIK3CA mutation

i
Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Entrez ID:
Related biomarkers:
PIK3CA mutation
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
PIK3CA mutation
Breast Cancer
BKM120
Sensitive: B - Late Trials
PIK3CA mutation
Breast Cancer
alpelisib
Sensitive: B - Late Trials
PIK3CA mutation
Triple Negative Breast Cancer
GDC-0068
Sensitive: B - Late Trials
PIK3CA mutation
CRC
panitumumab
Resistant: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
neratinib
Resistant: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
lapatinib
Resistant: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
PIK3CA mutation
CRC
atezolizumab + cobimetinib
Sensitive: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
everolimus
Sensitive: B - Late Trials
PIK3CA mutation
NSCLC
erlotinib
Resistant: B - Late Trials
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + MEN1611
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
Uterine Cancer
copanlisib
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
HER2 Positive Breast Cancer
MEN1611
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
Breast Cancer
palbociclib
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
Ovarian Cancer
CYH33
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
Breast Cancer
MEN1611
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
Breast Cancer
GDC-0032
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
SCCHN
alpelisib
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
alpelisib + fulvestrant
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation
NSCLC
U3-1402
Sensitive: C3 – Early Trials
PIK3CA mutation
Triple Negative Breast Cancer
everolimus
Sensitive: C3 – Early Trials
PIK3CA mutation
Urothelial Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PIK3CA mutation
SCCHN
temsirolimus
Sensitive: C3 – Early Trials
PIK3CA mutation
NSCLC
X-396
Resistant: C3 – Early Trials
PIK3CA mutation
Breast Cancer
bevacizumab
Sensitive: C3 – Early Trials
PIK3CA mutation
Breast Cancer
ribociclib
Sensitive: C3 – Early Trials
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
fulvestrant + anastrozole
Sensitive: C3 – Early Trials
PIK3CA mutation
Breast Cancer
CDK6 inhibitor
Resistant: C3 – Early Trials
PIK3CA mutation
Breast Cancer
CDK4 inhibitor
Resistant: C3 – Early Trials
PIK3CA mutation
Liposarcoma
copanlisib
Sensitive: C3 – Early Trials
PIK3CA mutation
NSCLC
osimertinib
Resistant: C3 – Early Trials
PIK3CA mutation
Estrogen Receptor Positive Breast Cancer
letrozole
Sensitive: C3 – Early Trials
PIK3CA mutation
CRC
trametinib + dabrafenib
Sensitive: C3 – Early Trials
PIK3CA mutation
Head and Neck Cancer
GDC-0032
Sensitive: C3 – Early Trials
PIK3CA mutation
Gastric Cancer
nivolumab
Sensitive: C3 – Early Trials
PIK3CA mutation
SCCHN
cetuximab
Resistant: C3 – Early Trials
PIK3CA mutation
Lung Non-Small Cell Squamous Cancer
GDC-0032
Sensitive: C3 – Early Trials
PIK3CA mutation
SCCHN
cetuximab + alpelisib
Sensitive: C3 – Early Trials
PIK3CA mutation
Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
PIK3CA mutation
CRC
cetuximab
Resistant: C3 – Early Trials
PIK3CA mutation
Solid Tumor
LY2606368 + LY3023414
Sensitive: C3 – Early Trials
PIK3CA mutation
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
PIK3CA mutation
Hormone Receptor Positive Breast Cancer
everolimus + exemestane
Sensitive: C3 – Early Trials
PIK3CA mutation
CRC
FOLFOX
Resistant: C3 – Early Trials
PIK3CA mutation
CRC
CAPOX
Resistant: C3 – Early Trials
PIK3CA mutation
HER2 Positive Breast Cancer
trastuzumab + alpelisib + LJM-716
Sensitive: C3 – Early Trials
PIK3CA mutation
Cervical Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
PIK3CA mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
PIK3CA mutation
NSCLC
alpelisib
Sensitive: C4 – Case Studies
PIK3CA mutation
Ampulla of Vater Carcinoma
everolimus
Sensitive: C4 – Case Studies
PIK3CA mutation
Breast Cancer
CYH33
Sensitive: C4 – Case Studies
PIK3CA mutation
Gastric Cancer
alpelisib
Sensitive: D – Preclinical
PIK3CA mutation
Breast Cancer
PP242
Sensitive: D – Preclinical
PIK3CA mutation
Triple Negative Breast Cancer
crizotinib + sunitinib
Sensitive: D – Preclinical
PIK3CA mutation
Triple Negative Breast Cancer
gefitinib + everolimus
Sensitive: D – Preclinical
PIK3CA mutation
NSCLC
GDC-0941
Sensitive: D – Preclinical
PIK3CA mutation
Estrogen Receptor Positive Breast Cancer
ribociclib + SNS-510
Sensitive: D – Preclinical
PIK3CA mutation
Estrogen Receptor Positive Breast Cancer
palbociclib + SNS-510
Sensitive: D – Preclinical
PIK3CA mutation
HER2 Positive Breast Cancer
CCT128930
Sensitive: D – Preclinical
PIK3CA mutation
Ovarian Cancer
CERC-006
Sensitive: D – Preclinical
PIK3CA mutation
Breast Cancer
TAK-228
Sensitive: D – Preclinical
PIK3CA mutation
Colon Cancer
PF-05212384 + PD-0325901
Sensitive: D – Preclinical
PIK3CA mutation
Thyroid Gland Carcinoma
temsirolimus + MK-2206
Sensitive: D – Preclinical
PIK3CA mutation
Endometrial Cancer
temsirolimus
Sensitive: D – Preclinical
PIK3CA mutation
Endometrial Cancer
GDC-0941
Sensitive: D – Preclinical
PIK3CA mutation
Endometrial Cancer
RTB101
Sensitive: D – Preclinical
PIK3CA mutation
Head and Neck Cancer
celecoxib
Sensitive: D – Preclinical
PIK3CA mutation
Breast Cancer
trastuzumab + MEN1611
Sensitive: D – Preclinical
PIK3CA mutation
Thyroid Gland Carcinoma
MK-2206
Sensitive: D – Preclinical
PIK3CA mutation
Gastric Cancer
AZD5363
Sensitive: D – Preclinical
PIK3CA mutation
SCCHN
tipifarnib
Sensitive: D – Preclinical
PIK3CA mutation
SCCHN
cetuximab + AZD8055
Sensitive: D – Preclinical
PIK3CA mutation
SCCHN
GDC-0032
Sensitive: D – Preclinical
PIK3CA mutation
Melanoma
vemurafenib
Resistant: D – Preclinical
PIK3CA mutation
Breast Cancer
alpelisib + abemaciclib
Sensitive: D – Preclinical
PIK3CA mutation
Cervical Cancer
neratinib + copanlisib
Sensitive: D – Preclinical
PIK3CA mutation
Breast Cancer
mTORC1 inhibitor
Sensitive: D – Preclinical
PIK3CA mutation
Triple Negative Breast Cancer
epirubicin
Resistant: D – Preclinical
PIK3CA mutation
Endometrial Cancer
GDC-0068
Sensitive: D – Preclinical
PIK3CA mutation
Adenoid Cystic Carcinoma
PI3K inhibitor
Sensitive: D – Preclinical
PIK3CA mutation
Endometrial Cancer
LY3023414
Sensitive: D – Preclinical
PIK3CA mutation
CRC
ribociclib + alpelisib
Sensitive: D – Preclinical